June 22 (Reuters) - Cochlear Ltd (COH) :
- UK COMPETITION AND MARKETS AUTHORITY PUBLISHED ITS FINAL REPORT IN RESPECT OF COCHLEAR'S ACQUISITION OF OTICON MEDICAL
- CMA CONCLUDED THAT COCHLEAR'S ACQUISITION OF OTICON MEDICAL'S COCHLEAR IMPLANTS BUSINESS DOES NOT RAISE COMPETITION CONCERNS
- INTEGRATION COSTS ARE YET TO BE DETERMINED AND ARE CURRENTLY ESTIMATED TO BE A$30-60 MILLION
- COCHLEAR'S ACQUISITION OF OTICON MEDICAL'S COCHLEAR IMPLANTS BUSINESS IS PERMITTED TO PROCEED
- CMA CONCLUDED CO'S ACQUISITION OF OTICON MEDICAL'S BONE CONDUCTION IMPLANTS BUSINESS WOULD RESULT IN SUBSTANTIAL LESSENING OF COMPETITION IN UK
- OTICON MEDICAL'S COCHLEAR IMPLANT BUSINESS IS EXPECTED TO ADD AROUND A$10 MILLION TO ANNUAL REVENUE
- COCHLEAR AND DEMANT WILL NOW PURSUE A TRANSFER OF OTICON MEDICAL'S CI BUSINESS AT A ZERO HEADLINE PURCHASE PRICE
- COCHLEAR CONTINUES TO TARGET LONG-TERM NET PROFIT MARGIN OF 18%
- TRANSACTION IS EXPECTED TO CLOSE BY DECEMBER 2023
- CMA PROHIBITED COCHLEAR'S ACQUISITION OF OTICON MEDICAL'S BONE CONDUCTION IMPLANTS BUSINESS
Add to My Watchlist
What is My Watchlist?